Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ulka Vaishampayan

Showing results (171-180 of 176) with videos related to

Pageof 18
Sort By:
You have reached the last page of results.This site can display upto 176 results.
European Urology Focus|July 30, 2017
Robot-assisted Versus Open Radical Cystectomy in Patients Receiving Perioperative Chemotherapy for Muscle-invasive Bladder Cancer: The Oncologist's Perspective from a Multicentre StudyAndrea Necchi, Gregory R Pond, Marc C Smaldone, et al.
The Lancet. Oncology|March 5, 2019
Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort studyNieves Martínez Chanzá, Wanling Xie, Mehmet Asim Bilen, et al.
Clinical Genitourinary Cancer|December 6, 2016
Impact of Sequencing Targeted Therapies With High-dose Interleukin-2 Immunotherapy: An Analysis of Outcome and Survival of Patients With Metastatic Renal Cell Carcinoma From an On-going Observational IL-2 Clinical Trial: PROCLAIM<sup>SM</sup>Joseph I Clark, Michael K K Wong, Howard L Kaufman, et al.
European Urology Focus|July 30, 2017
Lack of Effectiveness of Postchemotherapy Lymphadenectomy in Bladder Cancer Patients with Clinical Evidence of Metastatic Pelvic or Retroperitoneal Lymph Nodes Only: A Propensity Score-based AnalysisAndrea Necchi, Luigi Mariani, Salvatore Lo Vullo, et al.
Urologic Oncology|August 17, 2025
Developing biomarkers and methods of risk stratification: Consensus statements from the International Kidney Cancer Symposium North America 2024 Think TankDaniel D Shapiro, Edwin Jason Abel, Laurence Albiges, et al.
The Lancet. Oncology|November 23, 2019
Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trialDaniel P Petrylak, Ronald de Wit, Kim N Chi, et al.
Pageof 18

Showing results (171-180 of 176) with videos related to

Sort By:
Pageof 18
You have reached the last page of results.This site can display upto 176 results.
European Urology Focus|July 30, 2017
Robot-assisted Versus Open Radical Cystectomy in Patients Receiving Perioperative Chemotherapy for Muscle-invasive Bladder Cancer: The Oncologist's Perspective from a Multicentre StudyAndrea Necchi, Gregory R Pond, Marc C Smaldone, et al.
The Lancet. Oncology|March 5, 2019
Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort studyNieves Martínez Chanzá, Wanling Xie, Mehmet Asim Bilen, et al.
Clinical Genitourinary Cancer|December 6, 2016
Impact of Sequencing Targeted Therapies With High-dose Interleukin-2 Immunotherapy: An Analysis of Outcome and Survival of Patients With Metastatic Renal Cell Carcinoma From an On-going Observational IL-2 Clinical Trial: PROCLAIM<sup>SM</sup>Joseph I Clark, Michael K K Wong, Howard L Kaufman, et al.
European Urology Focus|July 30, 2017
Lack of Effectiveness of Postchemotherapy Lymphadenectomy in Bladder Cancer Patients with Clinical Evidence of Metastatic Pelvic or Retroperitoneal Lymph Nodes Only: A Propensity Score-based AnalysisAndrea Necchi, Luigi Mariani, Salvatore Lo Vullo, et al.
Urologic Oncology|August 17, 2025
Developing biomarkers and methods of risk stratification: Consensus statements from the International Kidney Cancer Symposium North America 2024 Think TankDaniel D Shapiro, Edwin Jason Abel, Laurence Albiges, et al.
The Lancet. Oncology|November 23, 2019
Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trialDaniel P Petrylak, Ronald de Wit, Kim N Chi, et al.
Pageof 18